Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | ACMSD | Q8TDX5 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL742865 | 0.86 | ACMSD (0.54) | ACMSDHSD17B10SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL745519 | 0.77 | ACMSD (0.49) | ACMSDHSD17B10CYP2D6CYP2C9MCL1 | |
| SCHEMBL2527550 | 0.75 | ERN1 (0.52) | KDM4EHPGDALDH1A1HSD17B10ERN1 | |
| SCHEMBL27542885 | 0.71 | ACMSD (0.62) | KDM4EHPGDALDH1A1ACMSDSLC6A2 | |
| SCHEMBL24895096 | 0.71 | KDM4E (0.59) | KDM4EHPGDALDH1A1HSD17B10LMNA | |
| SCHEMBL23143203 | 0.71 | KDM4E (0.66) | KDM4EHPGDALDH1A1ACMSDHSD17B10 | |
| SCHEMBL9534725 | 0.71 | KDM4E (0.66) | KDM4EHPGDALDH1A1ACMSDHSD17B10 | |
| SCHEMBL10873515 | 0.70 | ERN1 (0.58) | KDM4EHPGDALDH1A1ACMSDHSD17B10 | |
| SCHEMBL743927 | 0.69 | CA12 (0.49) | KDM4EHPGDALDH1A1HSD17B10ERN1 | |
| SCHEMBL30746762 | 0.69 | MAPT (0.47) | KDM4EHPGDALDH1A1HSD17B10ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486404-A1 | METABOLIC BIOMARKERS OF DRUG-INDUCED CARDIOTOXICITY | Wisconsin Alumni Research Foundation (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011044253-A1 | METABOLIC BIOMARKERS OF DRUG-INDUCED CARDIOTOXICITY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-04-14 | — | — | WO | claimed |
| US-20110081675-A1 | Metabolic Biomarkers Of Drug-Induced Cardiotoxicity | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-04-07 | — | — | US | claimed |
| EP-4729063-A2 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGbio, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BPGBIO INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | BPGBIO INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-2983654-B1 | TREATMENT OF CANCER USING COENZYME Q10 COMBINATION THERAPIES | BPGBIO INC (US) | 2025-11-12 | — | — | EP | disclosed |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | BPGBIO, INC. (US) | 2025-05-20 | — | — | US | disclosed |
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | BPGBIO, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | BERG LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | BERG, KARA ANN | 2022-06-30 | — | — | US | disclosed |
| WO-2011031503-A2 | METHODS FOR TREATMENT OF A SARCOMA USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | CYTOTECH LABS, LLC (US) | 2011-03-17 | — | — | WO | disclosed |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | BERG LLC | 2011-02-03 | — | — | US | disclosed |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | BERG LLC | 2011-01-27 | — | — | US | disclosed |
| WO-2010132440-A2 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132479-A2 | METHODS FOR THE DIAGNOSIS OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132502-A2 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| WO-2010132507-A2 | METHODS FOR TREATMENT OF DISEASE USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | CYTOTECH LABS, LLC (US) | 2010-11-18 | — | — | WO | disclosed |
| EP-2230312-A1 | Probe compound for detecting and isolating enzymes and means and methods using the same | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009052186-A1 | METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS | GEORGIA TECH RESEARCH CORPORATION (US) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209285-B2 | Methods for treatment of oncological disorders using an epimetabolic shifter (coenzyme Q10) | SLC25A20, NDUFB10, NDUFA10 | KDM4E 2057/4885HPGD 236/4885ALDH1A1 778/4885 |
| US-20260034073-A1 | COMBINATION THERAPY OF COENZYME Q10 AND RADIATION FOR TREATMENT OF GLIOMA | VEGFA, NDUFA10, NDUFB10 | KDM4E 1631/4885HPGD 334/4885ALDH1A1 455/4885 |
| US-20220202741-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFB10, NDUFA10, NDUFB5 | KDM4E 554/4885HPGD 305/4885ALDH1A1 766/4885 |
| US-20260091003-A1 | METHODS OF TREATMENT OF TEMOZOLOMIDE-RESISTANT GLIOMA USING COENZYME Q10 | NDUFA10, NDUFB10, NDUFA5 | KDM4E 828/4885HPGD 588/4885ALDH1A1 586/4885 |
| US-20110020312-A1 | METHODS FOR TREATMENT OF METABOLIC DISORDERS USING EPIMETABOLIC SHIFTERS, MULTIDIMENSIONAL INTRACELLULAR MOLECULES, OR ENVIRONMENTAL INFLUENCERS | PC, GLS2, PCK2 | KDM4E 2944/4885HPGD 636/4885ALDH1A1 867/4885 |
| US-20110027247-A1 | METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) | SLC25A20, NDUFB10, NDUFA10 | KDM4E 2057/4885HPGD 236/4885ALDH1A1 778/4885 |
| US-11452699-B2 | Method of treating or preventing tumors of the central nervous system | NDUFB10, NDUFA10, COQ8A | KDM4E 3221/4885HPGD 337/4885ALDH1A1 1181/4885 |
| US-12303471-B2 | Methods of treatment of temozolomide-resistant glioma using coenzyme Q10 | NDUFB10, NDUFA10, NDUFB5 | KDM4E 554/4885HPGD 305/4885ALDH1A1 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.